Prognostic value of circulating tumor DNA in different cancer types detected by ultra-low-pass whole-genome sequencing: a systematic review and patient-level survival data meta-analysis
Carcinogenesis · 20.01.2025 · 46 (1)
DOI: 10.1093/carcin/bgae073 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Carcinogenesis, online erschienen am 16.11.2024. Verfasst von Miguel Sogbe und 5 weiteren Autor:innen. Beteiligte Einrichtung: Liver Unit and HPB Oncology Area, Clinica Universidad de Navarra, Av Pio XII 36, 31008, Pamplona, Spain. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Neoplasms, Biomarkers, Tumor, Whole Genome Sequencing. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Agencia Estatal de Salud, Asociación Española Contra el Cancer, Fundacion Echebano.
Abstract (Originalsprache)
Ultra-low-pass whole-genome sequencing (ULP-WGS) (≤0.5 × coverage) of plasma cell-free DNA (cfDNA) has emerged as a low-cost, promising tool to assess the circulating tumor DNA (ctDNA) fraction. This meta-analysis aims to summarize the current findings and comprehensively investigate the prognostic value of baseline ctDNA detected by ULP-WGS in solid tumors. A systematic review was carried out by searching PubMed/MEDLINE and Scopus databases to identify eligible studies conducted between January 2014 and January 2024. Inclusion criteria comprised studies with reported overall survival and progression-free survival outcomes across therapy-naïve patients with different solid tumors. All patients underwent baseline ULP-WGS of plasma cfDNA and were categorized as ctDNA positive (tumor fraction ≥10%) or negative (tumor fraction <10%). A one-stage meta-analysis was performed using patient-level survival data reconstructed from published articles. A Cox proportional hazards model with shared frailty was used to assess the difference in survival between arms. A total of six studies, comprising 620 patients (367 negative ctDNA and 253 positive ctDNA), were included in the overall survival analysis, while five studies, involving 349 patients (212 negative ctDNA and 137 positive ctDNA), were included in the progression-free survival analysis. The meta-analysis showed that patients with baseline positive ctDNA had a significantly higher risk of death (HR = 2.60, 95% CI: 2.01–3.36) and disease progression (HR = 2.28, 95% CI: 1.71–3.05) compared to those with negative ctDNA. The presence of a positive ctDNA at baseline is associated with increased risk of death and progression in patients with same-stage cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Liver Unit and HPB Oncology Area, Clinica Universidad de Navarra, Av Pio XII 36, 31008, Pamplona, Spain.
- HPB and Liver Transplant Unit, Department of General Surgery and HPB Oncology Area, Clinica Universidad de Navarra, Av Pio XII 36, 31008, Pamplona, Spain.
- Liver Unit and HPB Oncology Area, Clinica Universidad de Navarra, Calle Marquesado de Santa Marta 1, 28027, Madrid, Spain.
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Av Monforte de Lemos 3-5, 28029, Madrid, Spain.
- Instituto de Investigación Sanitaria de Navarra (IdiSNA), Calle Irunlarrea 3, 31008, Pamplona, Spain.
- Center for Applied Medical Research (CIMA), RNA and DNA Medicine Program, University of Navarra, Av Pio XII 55, 31008, Pamplona, Spain.
ORCID-Profile: Miguel Sogbe, Daniel Aliseda
Förderung
- Agencia Estatal de Salud
- Asociación Española Contra el Cancer
- Fundacion Echebano
Zitieren
APA
Sogbe, M., Aliseda, D., Sangro, P., de la Torre-Aláez, M., Sangro, B., & Argemi, J. (2025). Prognostic value of circulating tumor DNA in different cancer types detected by ultra-low-pass whole-genome sequencing: a systematic review and patient-level survival data meta-analysis. Carcinogenesis, 46(1). https://doi.org/10.1093/carcin/bgae073
Vancouver
Sogbe M, Aliseda D, Sangro P, de la Torre-Aláez M, Sangro B, Argemi J. Prognostic value of circulating tumor DNA in different cancer types detected by ultra-low-pass whole-genome sequencing: a systematic review and patient-level survival data meta-analysis. Carcinogenesis. 2025;46(1). doi:10.1093/carcin/bgae073
BibTeX
@article{Sogbe2025,
author = {Sogbe, Miguel and Aliseda, Daniel and Sangro, Paloma and de la Torre-Aláez, Manuel and Sangro, Bruno and Argemi, Josepmaria},
title = {Prognostic value of circulating tumor DNA in different cancer types detected by ultra-low-pass whole-genome sequencing: a systematic review and patient-level survival data meta-analysis},
journal = {Carcinogenesis},
year = {2025},
volume = {46},
number = {1},
doi = {10.1093/carcin/bgae073}
}
EUVIMED